• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Neoplastic Disorders
    191 Drugs classified under this biological system


    All the biological system drugs

    Filter by letter: ALL A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
    Abelcet
    Abic
    RX
    partial basket chart
    Abelcet

    Antibiotics. Amphotericin B 5mg/ml.
    VIAL (Concent. for susp.for infus.):
    10×20ml. IV infus. at 5 mg/kg at a rate of
    2.5 mg/kg/hr. See lit.
    Tmt. of sev. invas. candidiasis. As 2nd line
    therapy for the tmt. of sev. syst. fungal
    infec. in pts. who have not responded to
    conventional amphotericin B or other
    syst. antifung. agents, in those who have
    renal impair. or other contra-indic. to
    conventional amphotericin B, or in pts.
    who have developed amphotericin B
    nephrotox.
    As 2nd line tmt. for invas. aspergillosis,
    cryptococcal meningitis and
    disseminated cryptococcosis in HIV pts.,
    fusariosis, coccidiomycosis, zygomycosis
    and blastomycosis.
    C/I: Hypersens.

    Abiplatin 1 mg/ml
    Salomon, Levin & Elstein Ltd
    RX
    partial basket chart
    Abiplatin 1 mg/ml

    Alkylating Agent (platinum analog). Cisplatin 1 mg/ml.
    VIALS: 1 x 100 ml, 50 ml. See lit.
    Palliative in add. to other modalities
    in
    tmt. metastat. testic. and ovar. cancer,
    advanced bladder cancer.

    Abiraterone Teva 250 mg
    Teva
    RX
    partial basket chart
    Abiraterone Teva 250 mg

    Anti-Androgen. Abiraterone Acetate 250 mg.
    TABS.: 120.
    Intended  for male pts. only. 1,000 mg (4×250mg tabs.) once dly. in comb. with prednisone.
    Indicated in comb. with prednisone for the tmt. of pts. with metastat. castration-resist. prostate cancer.
    C/I: Hypersensitivity to active substance or any of its excipients. Use in female patients. Severe hepatic impairment.

    Abitrexate
    Salomon, Levin & Elstein Ltd
    RX
    partial basket chart
    Abitrexate

    Folic Acid Analog. Methotrexate 25 mg/ml.
    VIAL (sol. for inj.): 25 mg/ ml X 2 ml, 4 ml,
    8 ml, 20 ml, 40 ml. Dose must be ajust.
    individ. for each pt. accord. to med.
    cond. See lit.
    Antineopl. Chemother.
    Tmt. of gestational choriocarcinoma,
    chorioadenoma destruens and
    hydatidiform mole. Palliation of ALL. Tmt.
    and proph. of menin. leukemia.
    Greatest effect has been observed in
    palliation of acute lymphoblast.(stemcell)
    leukemias in child. In comb. with
    other anticancer agents, may be used for
    the induc. of remis.,but is most common.
    used in the mainten. of induced remis.
    May be used alone, or in comb. with other
    antineoplastic drugs, in the manag. of
    breast canc., epidermoid cancers of the
    head and neck, lung cancer (partic.
    squamous cell ,small cell types), bladder
    cancer and osteogenic cancer. Tmt. of the
    advan.stages (III and IV, Peter’s Staging
    system) of lymphosarcoma, partic. in
    child., and in advanced cases of mycosis
    fungoides.
    Psoriasis. Indic. only in the sympt. control
    of sev. recalcitrant, disabling psoriasis
    which is not adeq. responsive to other
    forms of therapy, and only when the diag.
    has been established, as by biopsy and/or
    after dermat. consult. RA:Tmt. of selec.
    adul.with sev. RA, only when the diag. has
    been well established accord. to rheumat.
    standards, with inadeq. response to other
    forms of antirheum. ther., includ. full dose
    NSAIDs and usually a trial of at least one
    or more dis.-modif. antirheum. drugs.
    C/I: Pregnancy, lact., pts. in poor state of
    nutrition, sev. ren. impair. (crCL <20 ml/
    min), sev. liver impair., bone marrow
    hypoplasia, leucopenia,
    thrombocytopenia, anemia, alcohol
    abuse, hypersens. and lung toxic.due to
    methotrexate, serious, acute or chronic
    infect. such as tuberculosis and HIV,
    ulcers of the oral cavity and known
    active GI ulcer dis. Concur. vaccin. with
    live vaccines.

    Adcetris 50 mg
    Takeda
    RX
    partial basket chart
    Adcetris 50 mg

    Monoclonal Antibody. Brentuximab Vedotin 50 mg.
    VIAL (Pwdr. for conc. for solution for IV infus.): 1 x 50 mg. The recom. dose is 1.8 mg/kg administ. as an IV infus. over 30 min. every 3 wks. If the pt. weight >100 kg, the dose calcul. should use 100 kg. Tmt. should be cont. until dis. progress. or unaccep.tox. Pts. who achieve stab. dis. or better should receive a minim. of 8 cycles and up to a max. of 16 cycles (approx. 1 year). Pts. with CTCL should receive up to 16 cyclesDose should be individ. ajust in pts. with new or worsen. periph. sens./motor neuropath., neutpropen. The recomm. start.  dose in pts with sev. renal impair or hep.  impair. is 1.2 mg/ kg admin. as IV infus. over 30 min. every 3 wks. See lit.
    Tmt. of adult pts. with relapsed or refractory CD30+ Hodgkin lymphoma (HL). Follow. autologous stem cell transplant (ASCT) or follow. at least two prior therapies when ASCT or multi-agent chemother. is not a tmt. option. Tmt. of adult pts. with CD30+ HL at incr. risk of relapse or progress. follow. ASCT. Tmt. of adult pts. with relapsed or refract. system. anaplastic large cell lymphoma (sALCL). Tmt. of adult pts. with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior syst.  ther.
    C/I: Hypersens., comb. use with Bleomycin.

    Afinitor
    Novartis
    RX
    partial basket chart
    Afinitor

    Protein Kinase Inhibitor. Everolimus 2.5, 5, 10 mg.
    TABS: 30 x 2.5 mg, 5 mg, 10 mg. Tmt. to
    be initiated by physician experienced
    in the use of anticancer ther. Orally
    once dly., at the same time ev. d. See
    lit.
    Tmt. pts. with advanced ren. cell
    carcinoma aft. fail. of tmt. with sunitinib or
    sorafenib. Tmt. pts. with SEGA assoc. with
    tuberous sclerosis complex who req. ther.
    intervent.
    but not candidates for curative surg.
    resect. Effect. based on analys. of change
    in SEGA vol. Clin. benefit in improvement
    dis.-relat,. sympts/increase in overall
    survival has not been demonstrat. Tmt.
    progress. neuroendocrine tumors
    pancreat. origin in pts. with unresect.,
    locally advanced/metastat. dis. Safety/
    effectivenss in tmt. carcinoid tumors have
    not been established. Tmt. of horm.
    receptor-pos., HER2/neu neg. advanc.
    breast canc. in combi. with exemestane in
    postmen. women w/o symp. visceral dis.
    after recur. or progress. following nonsteroid.
    aromat. inh.. Tmt. of adult pts.
    with renal angiomyolipoma and tuberous
    sclerosis comp., nor req. immediate surg.
    Effectiv. of the drug in tmt. of renal
    angiomyolipoma based on an analysis of
    durable obj. respons. in pts. treat. for a
    median of 8.3 mnths. Further follow-up of
    pts. is req. to determine long-term
    outcomes.
    Tmt. of unresect., local. advanc. /metastat.,
    well-different. (Grade 1/ Grade 2) nonfunct.
    neuroendocrine tumour. of GI or
    lung origin in adults with progress. dis.
    C/I: Hypersens. to active substances,
    other rapamycin derivs., excips.

    CLOSE